Project Atlas
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Company Overview
Project Atlas is an established U.S.-based Contract Development and Manufacturing Organization (CDMO) specializing in solid dose and small molecule drug products.
The company delivers end-to-end pharmaceutical services including:
Development
Manufacturing
Packaging
Operates under FDA-approved cGMP facilities.
Existing infrastructure and capabilities support expansion into additional dosage forms, including:
Other small molecules
Oral solutions
Topicals
Time-release formulations
Liposomal products
Key Strengths
20+ years of operational experience in regulated pharmaceutical manufacturing
Successful FDA inspection – May 2025
Successful DEA inspection – March 2025
Proven track record of passing multiple FDA/DEA inspections and client audits
Comprehensive infrastructure supporting Phase I clinical through commercial-scale production
Deeply experienced management and technical teams with expertise in:
• Formulation development
• Process scale-up
• Regulatory compliance
Expansion & Growth Strategy
The company is entering its next growth phase with a clear focus on higher-margin and higher-complexity services:
Entry into weight loss and high-potency (HPAPI) manufacturing
Expansion of clinical capabilities and formulation laboratories
Targeted CapEx investments to increase capacity in:
• Solvent recovery
• Packaging
• Sterile handling
Strategic business development to build and deepen long-term partnerships with U.S. and global pharmaceutical innovators
Use of Funds & Investment Terms
$10 million investment sought to accelerate commercial-scale growth
Primary uses:
Build out commercial operations and expand high-margin manufacturing
Purchase & qualify new commercial packaging and laboratory equipment
Upgrade solvent recovery, potency containment systems, and facility infrastructure
Strengthen sales, marketing, and business development capabilities
Enhance team training and technical expertise
Eligible for up to $1M in state grants and tax incentives
Investment Terms
Round: Seed / Bridge to Series A
Ask: $10 million
Pre-Money Valuation: $16 million
Post-Money Valuation: $26 million (~3.7× projected 2026 sales)
Targeted ROI: 3–5× within 3–5 years, driven by expanded capacity, higher-margin services, and growing client base
Additional Synergies & Strategic Value
Facility capacity already positioned to support new dosage forms and clinical-scale expansion
Opportunity for co-location of U.S. headquarters to improve client access and collaboration
Cross-selling potential at major industry trade events
Strong positioning for collaborative partnerships, including:
• Liquid dosage form leasing arrangements
• Early-stage biotech development partnerships
• Strategic alliances with emerging pharma innovators
Project Atlas offers a rare combination of proven regulatory track record, existing commercial infrastructure, and clear path to significantly higher-margin business in weight loss drugs, high-potency, and advanced formulations — with strong ROI potential in the rapidly growing CDMO sector.